Abstract: FR-PO0220
Preferences of Patients and Nephrologists for the Treatment of Anemia in CKD: Results from a Presurvey of a Nationwide Multicenter Survey Questionnaire Based on a Discrete Choice Experiment (DCE)
Session Information
- Anemia and Iron Metabolism
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Authors
- Niu, Qingyu, Peking University People’s Hospital, Beijing, China
- Zhang, Xiaolu, China National Health Development Research Centre, Beijing, China
- Li, Xue, China National Health Development Research Centre, Beijing, China
- Hu, Zhizhen, Hansoh Pharmaceutical Group Co Ltd, Jiangsu, China
- Xiao, Yongzhen, Hansoh Pharmaceutical Group Co Ltd, Jiangsu, China
- Zuo, Li, Peking University People’s Hospital, Beijing, China
Background
Anemia is a common complication of chronic kidney disease (CKD). Current treatment options include erythropoiesis-stimulating agents, hypoxia-inducible factor prolyl hydroxylase inhibitors, and erythropoietin mimetic peptides, with varying administration frequencies (e.g., once a day and three times a week orally, three times a week, every two weeks and every month subcutaneously injected). This study assessed patient and nephrologist preferences for renal anemia management.
Methods
This nationwide multicenter study developed its DCE questionnaire through literature review, interviews, and three pre-survey rounds. Pre-survey findings (Figures A and B) were obtained from 7 large general hospitals in different regions of China. The final study will include 800 nephrologists and 3,000 patients to report preferences on anemia treatment.
Results
The pre-survey cohort included 15 nephrologists and 45 patients. The key preference determining factors for nephrologists include drug efficacy, indications, contraindications, patient compliance, cost, etc. Notably, patients assigned greater importance to symptomatic improvement and administration modality compared to nephrologists'. The administration modality and frequency are both nephrologists and patients' concern. Some patients try to minimize the frequency of subcutaneous injections, such as using long-acting subcutaneous preparations once a month, or choosing a more frequent oral regimen to avoid the pain associated with subcutaneous injection.
Conclusion
This study leverages a DCE design to optimize personalized management for anemia with CKD. We believe that this nationwide multicenter survey based on DCE will provide more evidence on the preferences in anemia management.